Role of β2‐glycoprotein I in the pathogenesis of the antiphospholipid syndrome
Rheumatology & Autoimmunity, 2023 Antiphospholipid syndrome (APS) is typically characterized by increased levels of three classes of antiphospholipid antibodies, namely lupus anticoagulant, anti‐β2‐glycoprotein I (anti‐β2GPI), and anticardiolipin antibodies.
Jing Li, Xiangrui Zhu, Juan Feng
doaj +2 more sources
Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome [PDF]
Haematologica, 2019 Systemic lupus erythematosus is frequently associated with antiphospholipid syndrome. Patients with lupus-antiphospholipid syndrome are characterized by recurrent arterial/venous thrombosis, miscarriages, and persistent presence of autoantibodies against
Marisa Benagiano +17 more
doaj +2 more sources
β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. [PDF]
PLoS ONE, 2016 Angiogenesis is the process of new blood vessel formation, and it plays a key role in various physiological and pathological conditions. The β2-glycoprotein I (β2-GPI) is a plasma glycoprotein with multiple biological functions, some of which remain to ...
Wen-Chin Chiu +3 more
doaj +2 more sources
Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy [PDF]
Haematologica, 2022 β2-glycoprotein I (β2-GPI) is a serum protein widely recognized as the main target of antibodies present in patients with antiphospholipid syndrome (APS).
Paolo Macor +13 more
doaj +2 more sources
Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus [PDF]
Научно-практическая ревматология, 2022 The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood.The aim of this study – to determine the clinical significance ...
F. A. Cheldieva +5 more
doaj +2 more sources
Influence of anticardiolipin and anti‐β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification [PDF]
Research and Practice in Thrombosis and Haemostasis, 2019 Background Anticardiolipin (aCL) and anti‐β2 glycoprotein I (aβ2GPI) immunoglobulin (Ig) G/IgM antibodies are 2 of the 3 laboratory criteria for classification of antiphospholipid syndrome (APS).
Laura Vanoverschelde +4 more
doaj +2 more sources
Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. [PDF]
PLoS ONE, 2017 Domain I (DI) of beta-2-glycoprotein I (β2GPI) contains the immunodominant epitope for pathogenic antiphospholipid antibodies (aPL). DI is exposed in the linear form of the molecule but not in the circular form that comprises 90% of serum β2GPI.
Maria Gabriella Raimondo +8 more
doaj +2 more sources
ASSESSMENTS OF AUTOANTIBODY AND CYTOKINE CONTENTS IN TEENAGERS OF INDUSTRIAL CENTERS SCREENING EXAMINATION [PDF]
Acta Biomedica Scientifica, 2012 270 teenagers without acute inflammation signs at the moment of the examination living in the industrial centers of Eastern Siberia have been examined.
L. B. Masnaviyeva, I. V. Kudayeva
doaj +1 more source
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I. [PDF]
J Immunol, 2020 β2-Glycoprotein I (β2-GPI) is an abundant plasma glycoprotein with unknown physiological function and is currently recognized as the main target of antiphospholipid Abs responsible for complement activation and vascular thrombosis in patients with ...
Durigutto P +10 more
europepmc +2 more sources
Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review
Biomedicines, 2021 Antiphospholipid syndrome (APS) is a hypercoagulation condition associated with the incidence of heterogenic antiphospholipid antibodies (aPLs), which non-specifically affect hemostasis processes.
Pavla Bradacova +8 more
doaj +1 more source